These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 20038759)

  • 1. Multiple sclerosis immunology: The healthy immune system vs the MS immune system.
    Kasper LH; Shoemaker J
    Neurology; 2010 Jan; 74 Suppl 1():S2-8. PubMed ID: 20038759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD20 therapies in multiple sclerosis and experimental autoimmune encephalomyelitis - Targeting T or B cells?
    Agahozo MC; Peferoen L; Baker D; Amor S
    Mult Scler Relat Disord; 2016 Sep; 9():110-7. PubMed ID: 27645355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-beta mechanisms of action in multiple sclerosis.
    Dhib-Jalbut S; Marks S
    Neurology; 2010 Jan; 74 Suppl 1():S17-24. PubMed ID: 20038758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic aspects of multiple sclerosis.
    Boppana S; Huang H; Ito K; Dhib-Jalbut S
    Mt Sinai J Med; 2011; 78(2):207-20. PubMed ID: 21425265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid cells - targets of medication in multiple sclerosis.
    Mishra MK; Yong VW
    Nat Rev Neurol; 2016 Sep; 12(9):539-51. PubMed ID: 27514287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging concepts in autoimmune encephalomyelitis beyond the CD4/T(H)1 paradigm.
    Batoulis H; Addicks K; Kuerten S
    Ann Anat; 2010 Aug; 192(4):179-93. PubMed ID: 20692821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Close Encounters of the First Kind: Innate Sensors and Multiple Sclerosis.
    Fernández-Paredes L; de Diego RP; de Andrés C; Sánchez-Ramón S
    Mol Neurobiol; 2017 Jan; 54(1):101-114. PubMed ID: 26732593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axonal degeneration in multiple sclerosis: defining therapeutic targets by identifying the causes of pathology.
    Lee JY; Biemond M; Petratos S
    Neurodegener Dis Manag; 2015 Dec; 5(6):527-48. PubMed ID: 26619755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis.
    Taoufik E; Tseveleki V; Euagelidou M; Emmanouil M; Voulgari-Kokota A; Haralambous S; Probert L
    Neurodegener Dis; 2008; 5(1):32-7. PubMed ID: 18075273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of CD8+ T-cells in lesion formation and axonal dysfunction in multiple sclerosis.
    McDole J; Johnson AJ; Pirko I
    Neurol Res; 2006 Apr; 28(3):256-61. PubMed ID: 16687050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effector and regulatory B cells in Multiple Sclerosis.
    Staun-Ram E; Miller A
    Clin Immunol; 2017 Nov; 184():11-25. PubMed ID: 28461106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mechanism of action of glatiramer acetate treatment in multiple sclerosis.
    Racke MK; Lovett-Racke AE; Karandikar NJ
    Neurology; 2010 Jan; 74 Suppl 1():S25-30. PubMed ID: 20038760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging role of IL-16 in cytokine-mediated regulation of multiple sclerosis.
    Skundric DS; Cruikshank WW; Montgomery PC; Lisak RP; Tse HY
    Cytokine; 2015 Oct; 75(2):234-48. PubMed ID: 25703787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies in MS: mechanisms of action.
    Bielekova B; Becker BL
    Neurology; 2010 Jan; 74 Suppl 1(Suppl 1):S31-40. PubMed ID: 20038761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunology of multiple sclerosis: disease mechanisms and therapeutic targets.
    Holmøy T
    Minerva Med; 2008 Apr; 99(2):119-40. PubMed ID: 18431322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone and cytotoxic drugs' mechanisms of action.
    Vollmer T; Stewart T; Baxter N
    Neurology; 2010 Jan; 74 Suppl 1():S41-6. PubMed ID: 20038762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging immunopharmacological targets in multiple sclerosis.
    Farjam M; Zhang GX; Ciric B; Rostami A
    J Neurol Sci; 2015 Nov; 358(1-2):22-30. PubMed ID: 26440421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights for practice: where mechanism of action meets patient management.
    Lisak RP; Korngold S
    Neurology; 2010 Jan; 74 Suppl 1():S70-3. PubMed ID: 20038766
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of immune regulatory molecules in multiple sclerosis.
    Afshar B; Khalifehzadeh-Esfahani Z; Seyfizadeh N; Rezaei Danbaran G; Hemmatzadeh M; Mohammadi H
    J Neuroimmunol; 2019 Dec; 337():577061. PubMed ID: 31520791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology?
    Johnson AJ; Suidan GL; McDole J; Pirko I
    Int Rev Neurobiol; 2007; 79():73-97. PubMed ID: 17531838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.